Peter Schraml

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. doi request reprint Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia
    Peter Schraml
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Mod Pathol 22:31-6. 2009
  2. doi request reprint αv-Integrin isoform expression in primary human tumors and brain metastases
    Alexander Vogetseder
    Department of Pathology, Institute for Surgical Pathology, University Hospital Zurich, Switzerland
    Int J Cancer 133:2362-71. 2013
  3. doi request reprint Characterization of periostin isoform pattern in non-small cell lung cancer
    Laura Morra
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Lung Cancer 76:183-90. 2012
  4. doi request reprint Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
    Peter Schraml
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Oncol Rep 28:654-8. 2012
  5. ncbi request reprint The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma
    Silvia Casagrande
    Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland
    J Pathol 229:525-34. 2013
  6. pmc Relevance of periostin splice variants in renal cell carcinoma
    Laura Morra
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Am J Pathol 179:1513-21. 2011
  7. doi request reprint KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics
    Markus Rechsteiner
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    J Mol Diagn 15:299-311. 2013
  8. doi request reprint Whole genome and transcriptome amplification: practicable tools for sustainable tissue biobanking?
    Adriana von Teichman
    Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland
    Virchows Arch 461:571-80. 2012
  9. pmc Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma
    Gunther Boysen
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Neoplasia 14:535-46. 2012
  10. doi request reprint Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma
    Van Duc Luu
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 15:3297-304. 2009

Collaborators

Detail Information

Publications26

  1. doi request reprint Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia
    Peter Schraml
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Mod Pathol 22:31-6. 2009
    ..We propose that the different ciliation status of clear cell and papillary renal cell carcinoma may contribute, at least in part, to the different biological behaviors of these tumor types...
  2. doi request reprint αv-Integrin isoform expression in primary human tumors and brain metastases
    Alexander Vogetseder
    Department of Pathology, Institute for Surgical Pathology, University Hospital Zurich, Switzerland
    Int J Cancer 133:2362-71. 2013
    ..05). Also integrin αvβ6 expression was increased in brain metastases compared to primary breast cancer (p < 0.001)...
  3. doi request reprint Characterization of periostin isoform pattern in non-small cell lung cancer
    Laura Morra
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Lung Cancer 76:183-90. 2012
    ..In this study we investigated periostin expression at both RNA and protein level as well as the expression pattern of its splice isoforms in non-small cell lung cancer (NSCLC)...
  4. doi request reprint Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
    Peter Schraml
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Oncol Rep 28:654-8. 2012
    ..The MGMT promoter methylation status may be a promising predictive marker for temozolomide therapy in metastatic melanoma patients. Larger sample sizes may help to validate significant differences in survival type endpoints...
  5. ncbi request reprint The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma
    Silvia Casagrande
    Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland
    J Pathol 229:525-34. 2013
    ..Our results suggest PTPRJ as a member of a pVHL-controlled pathway whose suppression by HIF is critical for ccRCC development...
  6. pmc Relevance of periostin splice variants in renal cell carcinoma
    Laura Morra
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Am J Pathol 179:1513-21. 2011
    ..The presence of a tumor-associated periostin isoform suggests splice-specific regulation in RCC tissue...
  7. doi request reprint KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics
    Markus Rechsteiner
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    J Mol Diagn 15:299-311. 2013
    ..In summary, our workflow allows us to process 315 targets a week and provides the quality, flexibility, and speed needed to be integrated as standard procedure for mutational analysis in diagnostics...
  8. doi request reprint Whole genome and transcriptome amplification: practicable tools for sustainable tissue biobanking?
    Adriana von Teichman
    Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland
    Virchows Arch 461:571-80. 2012
    ..We conclude that for sustainable tissue biobanking, the use of WGA and WTA is a unique opportunity to provide researchers with sufficient amounts of nucleic acids, preferably from limited frozen tissue material...
  9. pmc Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma
    Gunther Boysen
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Neoplasia 14:535-46. 2012
    ....
  10. doi request reprint Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma
    Van Duc Luu
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 15:3297-304. 2009
    ..Reactivation of PAX2 has been frequently observed in clear cell renal cell carcinoma (ccRCC), a tumor type characterized by loss of von Hippel-Lindau (VHL) tumor suppressor function. The regulation of PAX2 expression in ccRCC is unknown...
  11. doi request reprint Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer
    Corinne Dahinden
    Department of Urology, University Hospital Zurich, Center for Systems Physiology and Metabolic Diseases, ETH Zurich, and Institute of Surgical Pathology, Zurich, Switzerland
    Clin Cancer Res 16:88-98. 2010
    ..Elucidating molecular pathways deregulated in ccRCC may point to novel prognostic parameters that facilitate planning of therapeutic approaches...
  12. pmc Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice
    Joachim Albers
    Institute of Physiology, University of Zurich, Zurich, Switzerland
    EMBO Mol Med 5:949-64. 2013
    ..As the majority of ccRCC is associated with functional inactivation of VHL, our findings suggest that for a subset of ccRCC, loss of p53 function represents a critical event in tumour development...
  13. doi request reprint Loss of PBRM1 expression is associated with renal cell carcinoma progression
    Rafal Pawłowski
    Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland
    Int J Cancer 132:E11-7. 2013
    ..Given the role of PBRM1 in chromatin modification, the gene expression pathways disrupted by the inactivation of this protein may lead to new treatment strategies for ccRCC...
  14. doi request reprint VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma
    Adriana von Teichman
    University Hospital Zurich, Institute of Surgical Pathology, Zurich, Switzerland
    Mod Pathol 24:571-8. 2011
    ..Maintenance of a strong subcellular p27 expression in all multilocular cystic renal cell carcinomas analyzed may in part explain the excellent prognosis of these tumor patients...
  15. pmc Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome
    Manfred Beleut
    Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland
    BMC Cancer 12:310. 2012
    ..In an attempt to uncover such molecular features in RCC, we used a novel, unbiased and integrative approach...
  16. pmc Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques
    Nicola L Schoenewolf
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Case Rep Oncol 5:280-9. 2012
    ..Melanoma is characterized by a high frequency of BRAF mutations. It is unknown if the BRAF mutation status has any predictive value for therapeutic approaches such as angiogenesis inhibition...
  17. ncbi request reprint VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations
    Markus P Rechsteiner
    Institute of Surgical Pathology, University Hospital Zurich, Switzerland
    Cancer Res 71:5500-11. 2011
    ..We therefore conclude that the specific impact of missense mutations may help to distinguish between driver and passenger mutations and may explain responses of ccRCC patients to HIF-targeted therapies...
  18. pmc Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer
    Zsuzsanna Varga
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    PLoS ONE 8:e58483. 2013
    ....
  19. pmc Periostin is up-regulated in high grade and high stage prostate cancer
    Verena Tischler
    Institute for Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    BMC Cancer 10:273. 2010
    ..Expression of periostin is an indicator of epithelial-mesenchymal transition in cancer but a detailed analysis of periostin expression in prostate cancer has not been conducted so far...
  20. pmc Tumor cell plasticity and angiogenesis in human melanomas
    Daniela Mihic-Probst
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    PLoS ONE 7:e33571. 2012
    ..0001). We suggest that the hypoxic microenvironment in metastases contributes to a phenotype switch allowing melanoma cells to physically contribute to blood vessel formation...
  21. ncbi request reprint Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma
    Daniela Mihic-Probst
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Int J Cancer 121:1764-70. 2007
    ..005). This suggests that BMI-1 mediated repression of p16(ink4a) may contribute to an increased aggressive behavior of stem cell-like melanoma cells...
  22. pmc Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing
    Dorothee Pflueger
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland Life Science Zurich PhD Program on Molecular and Translational Biomedicine, Zurich, Switzerland Competence Center for Systems Physiology and Metabolic Diseases, Zurich, Switzerland
    Neoplasia 15:1231-40. 2013
    ..0001, both). ..
  23. ncbi request reprint KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma
    Thomas Wiedl
    Division of Thoracic Surgery, Institute of Surgical Pathology, University Hospital Zurich, Raemistrasse 100, CH 8091 Zurich, Switzerland
    Cancer Genomics Proteomics 9:51-4. 2012
    ..In conclusion myeloblastin is a potential therapeutic target for human lung adenocarcinoma, indicating that the combination of activity-based proteomics with mutational analysis is a valid approach for the discovery of novel biomarkers...
  24. pmc Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors
    Barbara Ingold
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    PLoS ONE 4:e4775. 2009
    ..The discrepancy between promoter methylation and a lack of MGMT immunoreactivity argues for assessing MGMT promoter methylation both by immunohistochemical as well as by molecular approaches for diagnostic purposes...
  25. ncbi request reprint Integrin control of the transforming growth factor-β pathway in glioblastoma
    Patrick Roth
    Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland
    Brain 136:564-76. 2013
    ....
  26. doi request reprint A procedure for tissue freezing and processing applicable to both intra-operative frozen section diagnosis and tissue banking in surgical pathology
    Susanne Steu
    Department of Pathology, Institute of Surgical Pathology, Zurich University Hospital, Schmelzbergstrasse 12, Zurich, Switzerland
    Virchows Arch 452:305-12. 2008
    ....